Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
作者信息
Swanson Chad J, Zhang Yong, Dhadda Shobha, Wang Jinping, Kaplow June, Lai Robert Y K, Lannfelt Lars, Bradley Heather, Rabe Martin, Koyama Akihiko, Reyderman Larisa, Berry Donald A, Berry Scott, Gordon Robert, Kramer Lynn D, Cummings Jeffrey L
机构信息
Eisai Inc., Woodcliff Lake, NJ, USA.
Eisai Ltd., Hatfield, UK.
出版信息
Alzheimers Res Ther. 2022 May 21;14(1):70. doi: 10.1186/s13195-022-00995-9.
Abstract
摘要
相似文献
1
Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.对《一项使用抗Aβ原纤维抗体lecanemab治疗早期阿尔茨海默病的随机、双盲、2b期概念验证临床试验》的更正
Alzheimers Res Ther. 2022 May 21;14(1):70. doi: 10.1186/s13195-022-00995-9.
2
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.利斯卡尼单抗治疗早期阿尔茨海默病患者：来自 2 期概念验证研究随机和开放标签扩展的生物标志物、认知和临床效果的详细结果。
Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2.
3
Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease.唐氏综合征和阿尔茨海默病患者可溶性淀粉样β原纤维升高。
Mol Cell Neurosci. 2021 Jul;114:103641. doi: 10.1016/j.mcn.2021.103641. Epub 2021 Jun 4.
4
Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.BAN2401的安全性与耐受性——一项针对阿尔茨海默病的原纤维选择性Aβ抗体的临床研究
Alzheimers Res Ther. 2016 Apr 6;8(1):14. doi: 10.1186/s13195-016-0181-2.
5
Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.使用模拟模型评估lecanemab对早期阿尔茨海默病患者的长期健康结局
Neurol Ther. 2022 Jun;11(2):863-880. doi: 10.1007/s40120-022-00350-y. Epub 2022 Apr 25.
6
Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.在早期临床试验中，临床前阿尔茨海默病认知复合指标（PACC）、PACC5 和神经心理状态重复电池（RBANS）对淀粉样蛋白状态的敏感性-Atabecestat 2b/3 期
J Prev Alzheimers Dis. 2022;9(2):255-261. doi: 10.14283/jpad.2022.17.
7
A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.一项针对阿尔茨海默病中淀粉样β蛋白的新型8-羟基喹啉的随机探索性分子成像研究：PBT2-204 IMAGINE研究。
Alzheimers Dement (N Y). 2017 Nov 9;3(4):622-635. doi: 10.1016/j.trci.2017.10.001. eCollection 2017 Nov.
8
An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease.一种淀粉样β原纤维选择性抗体可预防阿尔茨海默病小鼠模型中的淀粉样蛋白形成。
Neurobiol Dis. 2009 Dec;36(3):425-34. doi: 10.1016/j.nbd.2009.08.007. Epub 2009 Aug 22.
9
Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.早期阿尔茨海默病患者淀粉样蛋白正电子发射断层扫描和血浆生物标志物的群体药代动力学-药效学分析。
CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1578-1591. doi: 10.1002/psp4.12862. Epub 2022 Sep 27.
10
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.阿尔茨海默病患者使用 solanezumab 的安全性和生物标志物效应。
Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5.
引用本文的文献
1
Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.阿尔茨海默病治疗方法的演变：从传统药物到药用植物、免疫疗法、微生物疗法和纳米疗法。
Pharmaceutics. 2025 Jan 17;17(1):128. doi: 10.3390/pharmaceutics17010128.
2
An 11-mer Synthetic Peptide Suppressing Aggregation of Aβ25-35 and Resolving Its Aggregated Form Improves Test Performance in an Aβ25-35-Induced Alzheimer's Mouse Model.一种 11 肽抑制 Aβ25-35 聚集并使其聚集形式解聚，改善 Aβ25-35 诱导的阿尔茨海默病小鼠模型的测试表现。
Biomolecules. 2024 Sep 29;14(10):1234. doi: 10.3390/biom14101234.
3
Plasma pTau181 enhances the prediction of future clinical decline in amyloid-positive mild cognitive impairment.血浆磷酸化tau蛋白181增强了对淀粉样蛋白阳性轻度认知障碍未来临床衰退的预测。
Alzheimers Dement (Amst). 2024 Jul 23;16(3):e12621. doi: 10.1002/dad2.12621. eCollection 2024 Jul-Sep.
4
Association of midlife air pollution exposures and residential road proximity with incident dementia: The Atherosclerosis Risk in Communities (ARIC) study.中年时期的空气污染暴露与居住道路临近与痴呆症发病的相关性：动脉粥样硬化风险社区研究（ARIC）。
Environ Res. 2024 Oct 1;258:119425. doi: 10.1016/j.envres.2024.119425. Epub 2024 Jun 13.
5
SKGQA, a Peptide Derived from the ANA/BTG3 Protein, Cleaves Amyloid-β with Proteolytic Activity.SKGQA，一种源自 ANA/BTG3 蛋白的肽段，具有蛋白水解活性，可切割淀粉样-β。
Biomolecules. 2024 May 15;14(5):586. doi: 10.3390/biom14050586.
6
Independent study demonstrates amyloid probability score accurately indicates amyloid pathology.独立研究表明淀粉样蛋白概率评分能准确指示淀粉样蛋白病理学。
Ann Clin Transl Neurol. 2023 May;10(5):765-778. doi: 10.1002/acn3.51763. Epub 2023 Mar 28.
Zotero 插件